[go: up one dir, main page]

WO2024249604A3 - Covalent inhibitors as anti-malarial agents - Google Patents

Covalent inhibitors as anti-malarial agents Download PDF

Info

Publication number
WO2024249604A3
WO2024249604A3 PCT/US2024/031628 US2024031628W WO2024249604A3 WO 2024249604 A3 WO2024249604 A3 WO 2024249604A3 US 2024031628 W US2024031628 W US 2024031628W WO 2024249604 A3 WO2024249604 A3 WO 2024249604A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
malarial agents
covalent inhibitors
infection
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/031628
Other languages
French (fr)
Other versions
WO2024249604A2 (en
Inventor
Daniel P. FLAHERTY
Ryan Dean IMHOFF
Caroline NG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska Lincoln
Purdue Research Foundation
University of Nebraska System
Original Assignee
University of Nebraska Lincoln
Purdue Research Foundation
University of Nebraska System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nebraska Lincoln, Purdue Research Foundation, University of Nebraska System filed Critical University of Nebraska Lincoln
Publication of WO2024249604A2 publication Critical patent/WO2024249604A2/en
Publication of WO2024249604A3 publication Critical patent/WO2024249604A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present application generally relates to compounds, pharmaceutical compositions and method to treat a patient with malaria related disease or Plasmodium infection. Particularly the method compromises the step of administering a therapeutically effective amount of the disclosed compounds or compositions, with or without one or more anti-infective agents, to the patient in need of relief from said infection. Methods of uses and composition matters are within the scope of this disclosure.
PCT/US2024/031628 2023-06-02 2024-05-30 Covalent inhibitors as anti-malarial agents Pending WO2024249604A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363470664P 2023-06-02 2023-06-02
US63/470,664 2023-06-02

Publications (2)

Publication Number Publication Date
WO2024249604A2 WO2024249604A2 (en) 2024-12-05
WO2024249604A3 true WO2024249604A3 (en) 2025-05-15

Family

ID=93658833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/031628 Pending WO2024249604A2 (en) 2023-06-02 2024-05-30 Covalent inhibitors as anti-malarial agents

Country Status (1)

Country Link
WO (1) WO2024249604A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140148436A1 (en) * 2003-11-21 2014-05-29 Array Biopharma, Inc. Akt protein kinase inhibitors
US20160194329A1 (en) * 2012-12-20 2016-07-07 Ucb Pharma S.A. Therapeutically Active Pyrazolo-Pyrimidine Derivatives
US20190016721A1 (en) * 2016-01-29 2019-01-17 Beijing Innocare Pharma Tech Co., Ltd. Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140148436A1 (en) * 2003-11-21 2014-05-29 Array Biopharma, Inc. Akt protein kinase inhibitors
US20160194329A1 (en) * 2012-12-20 2016-07-07 Ucb Pharma S.A. Therapeutically Active Pyrazolo-Pyrimidine Derivatives
US20190016721A1 (en) * 2016-01-29 2019-01-17 Beijing Innocare Pharma Tech Co., Ltd. Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Malaria", WIKIPEDIA, 9 July 2024 (2024-07-09), XP093314700, Retrieved from the Internet <URL:https://en.wikipedia.org/w/index.php?title=Malaria&oldid=1233569792> *
DATABASE PUBCHEM COMPOUND 21 October 2014 (2014-10-21), XP093314696, Database accession no. 84671631 *
DATABASE PUBCHEM COMPOUND 3 June 2010 (2010-06-03), XP093314695, Database accession no. 45487381 *

Also Published As

Publication number Publication date
WO2024249604A2 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
MY196455A (en) Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection
CR20210563A (en) Compounds and methods for the treatment of covid-19
MX2023003627A (en) 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer.
WO2009076170A3 (en) Combinations of therapeutic agents for treating cancer
EP1933833B8 (en) Therapy for the treatment of overactive bladder
BRPI0517567A (en) compound or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, pharmaceutical composition, uses of a compound or a pharmaceutically acceptable salt, solvate, or derivative thereof and a pharmaceutical composition, and process for preparing a compound
BR0315580A (en) Methylene Urea Derivatives
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
TW200420549A (en) Thiazole derivatives
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
DE602005013793D1 (en) THIAZONE DERIVATIVES WITH VAP-1-HEMMENDER EFFECT
MX2023003576A (en) Compound as akt kinase inhibitor.
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
WO2023150619A3 (en) Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
MX2022009197A (en) Methods of treatment for alpha-1 antitrypsin deficiency.
TW200639159A (en) Treatment of pain
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
BR112023021030A2 (en) BICYCLIC HETEROAROMATIC KLK5 INHIBITORS
PH12022550350A1 (en) Antimalarial agents
WO2024249604A3 (en) Covalent inhibitors as anti-malarial agents
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
WO2006113718A3 (en) Compositions for the treatment of neoplasms
WO2023150790A3 (en) Novel and highly selective sars-cov-2 mpro inhibitors
MX2024010408A (en) Dihydroquinazolinones and related analogs for inhibiting yap/taz-tead.